03:02 , Dec 23, 2005 |  BC Extra  |  Financial News

Nucryst prices IPO

Westaim (Alberta, Canada) subsidiary Nucryst (NCST; TSX:NCS) raised $45 million through the sale of 4.5 million shares at $10 in an IPO on NASDAQ and the Toronto Stock Exchange, giving the company a post-money valuation...
02:04 , Dec 3, 2005 |  BC Extra  |  Financial News

Nucryst proposes IPO

Westaim (Alberta, Canada) subsidiary Nucryst (Wakefield, Mass.) proposed to sell 5.8 million shares at $12-$14 through an IPO on NASDAQ and the Toronto Stock Exchange. A $13 share price would raise $75.4 million and value...
07:00 , Apr 25, 2005 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Apr 18, 2005 |  BioCentury  |  Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
08:00 , Jan 24, 2005 |  BioCentury  |  Finance

Ebb & Flow

It's only three weeks into January, and already there has been a healthy flow of paper. Three follow-ons, two note deals and an IPO are in the can. There's more to come, as at least...
08:00 , Jan 21, 2005 |  BC Extra  |  Financial News

Martek raises $75 million

MATK raised $75 million through the sale of 1.5 million shares at $49.10 in a follow-on underwritten by Citigroup; Adams Harkness; Needham; First Albany; and D.A. Davidson. The deal has a 229,000 share overallotment. MATK...
08:00 , Jan 17, 2005 |  BioCentury  |  Finance

Ebb & Flow

JPMorgan's 23rd Annual Healthcare Conference last week could be summed up in two words: rational optimism. Rational because companies and investors both agree that valuations aren't going to spiral upward out of control anytime soon....
08:00 , Jan 14, 2005 |  BC Extra  |  Financial News

Martek proposes follow-on

MATK proposed to sell 1.5 million shares in a follow-on underwritten by Citigroup; Adams Harkness; Needham; First Albany; and D.A. Davidson. If sold at Thursday's close of $46.78, MATK would raise $70 million before any...
08:00 , Nov 8, 2004 |  BC Week In Review  |  Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   SNUS will acquire Synt:em for an initial payment of about $10 million in stock. Synt:em shareholders...
08:00 , Nov 8, 2004 |  BioCentury  |  Finance

Ebb & Flow

The acquisition of French neurology and cancer play...